JP6867431B2 - 患者テーラーメイド型抗癌剤スクリーニング用システム - Google Patents
患者テーラーメイド型抗癌剤スクリーニング用システム Download PDFInfo
- Publication number
- JP6867431B2 JP6867431B2 JP2019088305A JP2019088305A JP6867431B2 JP 6867431 B2 JP6867431 B2 JP 6867431B2 JP 2019088305 A JP2019088305 A JP 2019088305A JP 2019088305 A JP2019088305 A JP 2019088305A JP 6867431 B2 JP6867431 B2 JP 6867431B2
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- patient
- tailor
- anticancer
- candidate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000002246 antineoplastic agent Substances 0.000 title claims description 175
- 229940041181 antineoplastic drug Drugs 0.000 title claims description 88
- 238000007877 drug screening Methods 0.000 title claims description 37
- 206010028980 Neoplasm Diseases 0.000 claims description 174
- 201000011510 cancer Diseases 0.000 claims description 172
- 238000000034 method Methods 0.000 claims description 48
- 230000002068 genetic effect Effects 0.000 claims description 37
- 238000012216 screening Methods 0.000 claims description 36
- 230000001093 anti-cancer Effects 0.000 claims description 21
- 238000010171 animal model Methods 0.000 claims description 18
- 210000001519 tissue Anatomy 0.000 claims description 18
- 229940034982 antineoplastic agent Drugs 0.000 claims description 16
- 229940125648 antineoplastic drug candidate Drugs 0.000 claims description 13
- 238000012258 culturing Methods 0.000 claims description 13
- 230000000694 effects Effects 0.000 claims description 12
- 238000004458 analytical method Methods 0.000 claims description 10
- 230000001747 exhibiting effect Effects 0.000 claims description 10
- 241001465754 Metazoa Species 0.000 claims description 9
- 108090000623 proteins and genes Proteins 0.000 claims description 8
- 238000013500 data storage Methods 0.000 claims description 5
- 108091005804 Peptidases Proteins 0.000 claims description 4
- 238000000338 in vitro Methods 0.000 claims description 4
- 239000003550 marker Substances 0.000 claims description 4
- 238000011218 seed culture Methods 0.000 claims description 4
- 206010006187 Breast cancer Diseases 0.000 claims description 3
- 208000026310 Breast neoplasm Diseases 0.000 claims description 3
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 3
- 230000003833 cell viability Effects 0.000 claims description 3
- 238000001914 filtration Methods 0.000 claims description 3
- 238000001727 in vivo Methods 0.000 claims description 3
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 3
- 201000002528 pancreatic cancer Diseases 0.000 claims description 3
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 3
- 239000007787 solid Substances 0.000 claims description 3
- 206010005003 Bladder cancer Diseases 0.000 claims description 2
- 206010009944 Colon cancer Diseases 0.000 claims description 2
- 208000032612 Glial tumor Diseases 0.000 claims description 2
- 206010018338 Glioma Diseases 0.000 claims description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 2
- 238000011789 NOD SCID mouse Methods 0.000 claims description 2
- 206010033128 Ovarian cancer Diseases 0.000 claims description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 2
- 206010060862 Prostate cancer Diseases 0.000 claims description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 2
- 208000006265 Renal cell carcinoma Diseases 0.000 claims description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 2
- 208000029742 colonic neoplasm Diseases 0.000 claims description 2
- 206010017758 gastric cancer Diseases 0.000 claims description 2
- 102000054766 genetic haplotypes Human genes 0.000 claims description 2
- 201000010536 head and neck cancer Diseases 0.000 claims description 2
- 208000014829 head and neck neoplasm Diseases 0.000 claims description 2
- 201000007270 liver cancer Diseases 0.000 claims description 2
- 208000014018 liver neoplasm Diseases 0.000 claims description 2
- 201000005202 lung cancer Diseases 0.000 claims description 2
- 208000020816 lung neoplasm Diseases 0.000 claims description 2
- 208000037819 metastatic cancer Diseases 0.000 claims description 2
- 208000011575 metastatic malignant neoplasm Diseases 0.000 claims description 2
- 230000035772 mutation Effects 0.000 claims description 2
- 238000011580 nude mouse model Methods 0.000 claims description 2
- 208000015347 renal cell adenocarcinoma Diseases 0.000 claims description 2
- 201000011549 stomach cancer Diseases 0.000 claims description 2
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 2
- 102000035195 Peptidases Human genes 0.000 claims 1
- 238000011579 SCID mouse model Methods 0.000 claims 1
- 230000010261 cell growth Effects 0.000 claims 1
- 239000003814 drug Substances 0.000 description 19
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 14
- 201000010099 disease Diseases 0.000 description 13
- 229940079593 drug Drugs 0.000 description 9
- 208000024891 symptom Diseases 0.000 description 8
- 238000005138 cryopreservation Methods 0.000 description 5
- 238000013537 high throughput screening Methods 0.000 description 5
- 238000010586 diagram Methods 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 238000000605 extraction Methods 0.000 description 4
- 238000012545 processing Methods 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 3
- 239000004365 Protease Substances 0.000 description 3
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 3
- 230000009702 cancer cell proliferation Effects 0.000 description 3
- 239000002577 cryoprotective agent Substances 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 230000002062 proliferating effect Effects 0.000 description 3
- 208000002491 severe combined immunodeficiency Diseases 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 239000002699 waste material Substances 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 2
- 206010027476 Metastases Diseases 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 239000000090 biomarker Substances 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 239000007795 chemical reaction product Substances 0.000 description 2
- 208000005017 glioblastoma Diseases 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 230000009401 metastasis Effects 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000004797 therapeutic response Effects 0.000 description 2
- 238000002689 xenotransplantation Methods 0.000 description 2
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 206010052358 Colorectal cancer metastatic Diseases 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 208000029462 Immunodeficiency disease Diseases 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 238000011529 RT qPCR Methods 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 239000012472 biological sample Substances 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000009795 derivation Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 230000007813 immunodeficiency Effects 0.000 description 1
- 238000012750 in vivo screening Methods 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 239000013610 patient sample Substances 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/15—Medicinal preparations ; Physical properties thereof, e.g. dissolubility
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0271—Chimeric vertebrates, e.g. comprising exogenous cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
- A61K49/0008—Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0693—Tumour cells; Cancer cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
- C12Q1/24—Methods of sampling, or inoculating or spreading a sample; Methods of physically isolating an intact microorganisms
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2207/00—Modified animals
- A01K2207/12—Animals modified by administration of exogenous cells
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/0331—Animal model for proliferative diseases
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/136—Screening for pharmacological compounds
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/10—Screening for compounds of potential therapeutic value involving cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Pathology (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Analytical Chemistry (AREA)
- Environmental Sciences (AREA)
- Urology & Nephrology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physics & Mathematics (AREA)
- General Engineering & Computer Science (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Animal Behavior & Ethology (AREA)
- Toxicology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Biophysics (AREA)
- Animal Husbandry (AREA)
- Biodiversity & Conservation Biology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Gastroenterology & Hepatology (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Hospice & Palliative Care (AREA)
- Rheumatology (AREA)
Description
このような背景下で、本発明者らは、より改善した癌関連疾患の患者テーラーメイド型治療剤をスクリーニングする方法を開発するために鋭意研究を重ねた結果、患者から取得した癌細胞を利用したin vivoスクリーニング方法とin vitro検証方法の両方を含む統合システムを開発し、前記システムを利用する場合、癌関連疾患の患者テーラーメイド型治療剤をより効果的にスクリーニングし、検証することができることを確認し、本発明を完成するに至った。
Claims (12)
- 患者テーラーメイド型抗癌剤スクリーニング方法であって、前記方法は以下:
(a)癌を有する患者の臨床情報及び癌の遺伝的情報を取得し、そして前記臨床及び遺伝的情報を根拠として候補抗癌剤を導出する工程、
(b)候補抗癌剤を、分離された癌患者由来癌組織から取得した単細胞化された癌細胞、または分離された癌患者由来癌組織から取得した単細胞化された癌細胞を培養して取得した培養された癌細胞にin vitroで処理して、処理された各候補抗癌剤の抗癌活性を測定して、候補抗癌剤からin vitroでの抗癌活性を示す患者テーラーメイド型抗癌剤候補群を選定する段階であって、
患者由来癌細胞は、以下:
(i)分離された前記癌患者由来癌組織を粉砕し、前記粉砕物から細胞分画を取得する段階と、
(ii)前記取得された細胞分画にタンパク質分解酵素を処理した後、ろ過及び遠心分離する段階
により取得されることを特徴とする、段階と、
(c)前記工程(b)の選定された患者テーラーメイド型抗癌剤候補の候補群を前記患者由来癌細胞を含む異種移植動物モデル(ヒトを除く)に処理して、前記抗癌剤候補群の抗癌効果をin vivoで確認する段階
を含み、
前記工程(a)及び(b)が自動アバタースキャナ装置によって行われ、
前記アバタースキャナ装置は、癌の遺伝的情報から適合する候補抗癌剤を導出することができる第1手段と、患者の癌組織から癌細胞を取得することができる第2手段と、前記癌細胞に前記導出された候補抗癌剤を処理し、候補抗癌剤の効果を分析することができる第3手段を含み、
前記アバタースキャナ装置は、培養システム、候補抗癌剤貯蔵所、候補抗癌剤分注器、細胞生存率測定器、データ保存装置、及びデータ分析装置を含み、
前記培養システムは、培地貯蔵所、細胞分注器、培地交換器、インキュベーター、攪拌機、及び廃液排出装置を含む、
前記方法。 - 前記(a)段階の候補抗癌剤は癌の遺伝的情報を利用して選別することを特徴とする請求項1に記載の患者テーラーメイド型抗癌剤スクリーニング方法。
- 前記癌の遺伝的情報は癌特異的SNP分析結果、癌特異的ハプロタイプ分析結果、癌特異的突然変異分析結果、及び癌特異的遺伝子マーカー分析結果から選択される一つ以上の情報であることを特徴とする請求項2に記載の患者テーラーメイド型抗癌剤スクリーニング方法。
- 前記培養システムは癌細胞を種培養する癌細胞種培養手段であることを特徴とする請求項1に記載の患者テーラーメイド型抗癌剤スクリーニング方法。
- 前記培養システムは癌細胞を増殖培養する癌細胞増殖培養手段であることを特徴とする請求項1に記載の患者テーラーメイド型抗癌剤スクリーニング方法。
- 前記(b)段階は患者由来癌細胞に候補抗癌剤を処理し、処理された各候補抗癌剤が抗癌活性を示すか否かを確認して、抗癌活性を示すことに確認された候補抗癌剤を患者テーラーメイド型抗癌剤候補群として選定することを特徴とする請求項1に記載の患者テーラーメイド型抗癌剤スクリーニング方法。
- 前記(c)段階は患者由来癌細胞を免疫不全動物に異種移植して作製された患者テーラーメイド型動物モデルを利用して行われることを特徴とする請求項1に記載の患者テーラーメイド型抗癌剤スクリーニング方法。
- 前記免疫不全動物は免疫不全マウスであることを特徴とする請求項7に記載の患者テーラーメイド型抗癌剤スクリーニング方法。
- 前記免疫不全マウスはヌードマウス、NODマウス、SCIDマウス、NOD‐SCIDマウス、NOG(NOD/SCID Il2rg‐/‐)マウスであることを特徴とする請求項8に記載の患者テーラーメイド型抗癌剤スクリーニング方法。
- 前記(b)段階で候補抗癌剤を処理する前、前記癌細胞の一部を凍結保存する段階をさらに含むことを特徴とする請求項1に記載の患者テーラーメイド型抗癌剤スクリーニング方法。
- 前記癌は固形癌であることを特徴とする請求項1に記載の患者テーラーメイド型抗癌剤スクリーニング方法。
- 前記固形癌は肝癌、膠腫、卵巣癌、大腸癌、頭頚部癌、膀胱癌、腎細胞癌、胃癌、乳癌、転移癌、前立腺癌、膵臓癌及び肺癌からなる群より選択されることを特徴とする請求項11に記載の患者テーラーメイド型抗癌剤スクリーニング方法。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2012-0143573 | 2012-12-11 | ||
KR20120143573A KR101327533B1 (ko) | 2012-12-11 | 2012-12-11 | 환자 맞춤형 항암제 선별용 시스템 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2017096417A Division JP2017195887A (ja) | 2012-12-11 | 2017-05-15 | 患者テーラーメイド型抗癌剤スクリーニング用システム |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2019150043A JP2019150043A (ja) | 2019-09-12 |
JP6867431B2 true JP6867431B2 (ja) | 2021-04-28 |
Family
ID=49857311
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2015547851A Pending JP2016501027A (ja) | 2012-12-11 | 2013-12-11 | 患者テーラーメイド型抗癌剤スクリーニング用システム |
JP2017096417A Pending JP2017195887A (ja) | 2012-12-11 | 2017-05-15 | 患者テーラーメイド型抗癌剤スクリーニング用システム |
JP2019088305A Active JP6867431B2 (ja) | 2012-12-11 | 2019-05-08 | 患者テーラーメイド型抗癌剤スクリーニング用システム |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2015547851A Pending JP2016501027A (ja) | 2012-12-11 | 2013-12-11 | 患者テーラーメイド型抗癌剤スクリーニング用システム |
JP2017096417A Pending JP2017195887A (ja) | 2012-12-11 | 2017-05-15 | 患者テーラーメイド型抗癌剤スクリーニング用システム |
Country Status (9)
Country | Link |
---|---|
US (3) | US20160103119A1 (ja) |
EP (1) | EP2933636B1 (ja) |
JP (3) | JP2016501027A (ja) |
KR (1) | KR101327533B1 (ja) |
CN (1) | CN104919315B (ja) |
ES (1) | ES2886512T3 (ja) |
SA (1) | SA113350064B1 (ja) |
SG (2) | SG11201504628UA (ja) |
WO (1) | WO2014092457A1 (ja) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101782005B1 (ko) * | 2015-05-28 | 2017-09-27 | 한국과학기술원 | 암미세환경 어레이 플랫폼 |
KR102557289B1 (ko) * | 2016-01-27 | 2023-07-20 | 연세대학교 산학협력단 | 미만형 종양의 환자 유래 이종이식 모델 및 이의 제조방법 |
KR101983547B1 (ko) * | 2016-04-04 | 2019-05-29 | 주식회사 싸이토젠 | 단기배양 혈중 암세포(ctc)를 활용한 개인 맞춤형 항암제 선별시스템 및 선별방법 |
KR101895207B1 (ko) * | 2016-05-12 | 2018-09-07 | 주식회사 싸이토젠 | 환자 유래 체액 종양세포를 활용한 맞춤형 항암제 선별방법 |
CA3026236C (en) | 2016-06-03 | 2021-01-26 | Samsung Life Public Welfare Foundation | Method for screening antibody using patient-derived tumor spheroids |
IT201700004017A1 (it) * | 2017-01-16 | 2018-07-16 | React4Life Srl | Bioreattore e metodo di utilizzo di detto bioreattore |
US10636512B2 (en) | 2017-07-14 | 2020-04-28 | Cofactor Genomics, Inc. | Immuno-oncology applications using next generation sequencing |
CN112334575A (zh) * | 2018-04-13 | 2021-02-05 | 上海立迪生物技术股份有限公司 | 从条件性重编程细胞获得动物模型的方法以及该动物模型用于筛选抗肿瘤药物的用途 |
CN108624561B (zh) * | 2018-05-26 | 2021-09-17 | 复旦大学 | 原代肿瘤细胞培养基、培养方法以及应用 |
CN115862890B (zh) * | 2022-08-31 | 2023-08-11 | 山东第一医科大学附属肿瘤医院(山东省肿瘤防治研究院、山东省肿瘤医院) | 一种抗癌药物筛选方法及系统 |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5424209A (en) * | 1993-03-19 | 1995-06-13 | Kearney; George P. | Automated cell culture and testing system |
US20070122406A1 (en) * | 2005-07-08 | 2007-05-31 | Xencor, Inc. | Optimized proteins that target Ep-CAM |
US9342657B2 (en) | 2003-03-24 | 2016-05-17 | Nien-Chih Wei | Methods for predicting an individual's clinical treatment outcome from sampling a group of patient's biological profiles |
EP1664340A1 (en) * | 2003-08-08 | 2006-06-07 | Canbas Co., Ltd. | Sensitivity test to predict efficacy of anti-cancer therapies |
KR100689107B1 (ko) * | 2004-05-25 | 2007-03-09 | 가톨릭대학교 산학협력단 | 세포독성 분석법과 결합된 다층 암세포 배양계를 이용한항암물질의 활성 측정 방법 |
JP2006166799A (ja) * | 2004-12-16 | 2006-06-29 | Motoko Iijima | 抗癌剤選択検査方式 |
CN101313221A (zh) * | 2005-09-21 | 2008-11-26 | Ccc诊断有限责任公司 | 用于个人化抗癌化疗(pac)的综合诊断检测方法 |
CA2623445A1 (en) | 2005-09-21 | 2007-03-29 | Ccc Diagnostics, Llc | Comprehensive diagnostic testing procedures for personalized anticancer chemotherapy (pac) |
EP1792978A1 (en) * | 2005-12-01 | 2007-06-06 | Stiftung Caesar Center of Advanced European Studies and Research | Means and methods for the isolation and characterization of cancer stem cells |
US20080113390A1 (en) | 2006-08-08 | 2008-05-15 | In Suk Han | Personalized assay for the identification of an effective therapy for cancer |
US8583380B2 (en) | 2008-09-05 | 2013-11-12 | Aueon, Inc. | Methods for stratifying and annotating cancer drug treatment options |
KR101046883B1 (ko) * | 2008-11-19 | 2011-07-06 | 재단법인 아산사회복지재단 | 항암제 치료약제에 대한 감수성을 일괄적으로 결정하는 방법 |
SG10201402346UA (en) | 2009-05-19 | 2014-10-30 | Vivia Biotech Sl | Methods for providing personalized medicine tests ex vivo for hematological neoplasms |
JP2011115106A (ja) * | 2009-12-04 | 2011-06-16 | Rei Medical Co Ltd | 癌細胞凝集塊およびその調製法 |
JP5809782B2 (ja) * | 2009-12-24 | 2015-11-11 | 株式会社ルネッサンス・エナジー・インベストメント | 癌組織由来細胞塊または癌細胞凝集塊の薬剤または放射線感受性評価方法 |
CN103250176A (zh) * | 2010-08-13 | 2013-08-14 | 智能医学公司 | 用于生产个性化定制药物产品的系统和方法 |
KR101371697B1 (ko) | 2011-02-07 | 2014-03-07 | 연세대학교 원주산학협력단 | 환자 맞춤형 암 치료 |
CA2831468A1 (en) * | 2011-04-04 | 2012-10-11 | Nestec S.A. | Methods for predicting and improving the survival of gastric cancer patients |
US20140047570A1 (en) * | 2011-04-19 | 2014-02-13 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Animal model of human cancer and methods of use |
-
2012
- 2012-12-11 KR KR20120143573A patent/KR101327533B1/ko active IP Right Grant
-
2013
- 2013-12-10 SA SA113350064A patent/SA113350064B1/ar unknown
- 2013-12-11 ES ES13863563T patent/ES2886512T3/es active Active
- 2013-12-11 SG SG11201504628UA patent/SG11201504628UA/en unknown
- 2013-12-11 SG SG10201903658QA patent/SG10201903658QA/en unknown
- 2013-12-11 EP EP13863563.6A patent/EP2933636B1/en active Active
- 2013-12-11 CN CN201380070033.7A patent/CN104919315B/zh active Active
- 2013-12-11 JP JP2015547851A patent/JP2016501027A/ja active Pending
- 2013-12-11 WO PCT/KR2013/011490 patent/WO2014092457A1/ko active Application Filing
- 2013-12-11 US US14/651,207 patent/US20160103119A1/en not_active Abandoned
-
2017
- 2017-05-15 JP JP2017096417A patent/JP2017195887A/ja active Pending
-
2019
- 2019-05-08 JP JP2019088305A patent/JP6867431B2/ja active Active
- 2019-12-06 US US16/705,492 patent/US20200110071A1/en not_active Abandoned
-
2023
- 2023-02-24 US US18/113,713 patent/US20230213501A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
US20200110071A1 (en) | 2020-04-09 |
WO2014092457A1 (ko) | 2014-06-19 |
CN104919315B (zh) | 2017-08-15 |
JP2017195887A (ja) | 2017-11-02 |
US20230213501A1 (en) | 2023-07-06 |
ES2886512T3 (es) | 2021-12-20 |
EP2933636B1 (en) | 2021-07-07 |
SA113350064B1 (ar) | 2016-04-05 |
EP2933636A4 (en) | 2017-03-22 |
JP2016501027A (ja) | 2016-01-18 |
CN104919315A (zh) | 2015-09-16 |
US20160103119A1 (en) | 2016-04-14 |
KR101327533B1 (ko) | 2013-11-08 |
SG10201903658QA (en) | 2019-05-30 |
JP2019150043A (ja) | 2019-09-12 |
SG11201504628UA (en) | 2015-07-30 |
EP2933636A1 (en) | 2015-10-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6867431B2 (ja) | 患者テーラーメイド型抗癌剤スクリーニング用システム | |
Bearer et al. | Multiparameter computational modeling of tumor invasion | |
JP6026653B2 (ja) | 患者オーダーメード型膠芽腫動物モデルの製造方法及びこれの用途 | |
Roelofs et al. | Breast tumour organoids: promising models for the genomic and functional characterisation of breast cancer | |
Busch et al. | The chick embryo as an experimental system for melanoma cell invasion | |
Kageyama et al. | Establishment of an orthotopic patient-derived xenograft mouse model using uveal melanoma hepatic metastasis | |
CN102265156B (zh) | 用于具有抗血管发生活性的抑制剂的生物标志 | |
Thong et al. | Tissue slice grafts of human renal cell carcinoma: an authentic preclinical model with high engraftment rate and metastatic potential | |
Wang et al. | Subrenal capsule grafting technology in human cancer modeling and translational cancer research | |
CN105121657A (zh) | 有关癌症发展及对治疗的反应的快速预测 | |
Gamble et al. | Quantification of glioblastoma progression in zebrafish xenografts: Adhesion to laminin alpha 5 promotes glioblastoma microtumor formation and inhibits cell invasion | |
US20190351076A1 (en) | Tumor cell xenograft model in zebrafish, and methods of constructing and using the same | |
Jensen et al. | Glioma spheroids obtained via ultrasonic aspiration are viable and express stem cell markers: a new tissue resource for glioma research | |
Li et al. | The merits of awake craniotomy for glioblastoma in the left hemispheric eloquent area: one institution experience | |
Welm et al. | Toward improved models of human cancer | |
Hachey et al. | A human vascularized microtumor model of patient-derived colorectal cancer recapitulates clinical disease | |
Gupta et al. | Disease models of breast cancer | |
Oraiopoulou et al. | Phenocopying glioblastoma: A review | |
Han et al. | Personalized primary tumor xenograft model established for the pre-clinical trial to guide postoperative chemotherapy | |
Aldape et al. | Models of malignant glioma | |
Hollawell et al. | BIOL-22. CHILDREN’S BRAIN TUMOR NETWORK PRECLINICAL TUMOR MODELS DEVELOPMENT AND SHARING PLATFORM: COLLABORATIVE MODEL EMPOWERING PEDIATRIC BRAIN TUMOR DISCOVERY AND GLOBAL RESEARCH | |
Mannelli et al. | Rapid Tissue Donation (RTD) for Oncology Research | |
Morrato et al. | 2564 Designing for dissemination: Characteristics of Clinical and Translational Science Award (CTSA) hubs as adopters of clinical and translational science innovation | |
Sherman et al. | Low-Grade Gliomas | |
Pruneri et al. | Quality Criteria in Oncology: Lessons learned from the B4MED Biobank |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20190508 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20190508 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20190510 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20200602 |
|
A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20200623 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20200623 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20200901 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200911 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20201117 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20210316 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20210408 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6867431 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |